Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118851 | 0.80 | KCNH2 (0.42) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL23825277 | 0.79 | PDE4A (0.34) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL3118699 | 0.79 | DYRK1A (0.48) | RAF1DYRK1A | |
| SCHEMBL3121332 | 0.72 | MAP4K4 (0.41) | DYRK1AMAP4K4 | |
| SCHEMBL15884843 | 0.71 | PDE4A (0.41) | PDE4APDE4CPDE4DMAP4K4 | |
| SCHEMBL3124457 | 0.71 | PDE4A (0.42) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL30625738 | 0.71 | PDE4A (0.42) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL23825268 | 0.71 | PDE4A (0.38) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL29069640 | 0.68 | PDE4A (0.38) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL21247743 | 0.67 | CA1 (0.40) | PDE4APDE4CPDE4DCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | PDE4A 223/4885PDE4C 424/4885PDE4D 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.